ArticleTranslational cancer research2025
Exploration of efferocytosis-related genes as potential therapeutic targets in endometrial cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Efferocytosis is involved in the occurrence and development of various malignancies, but its role in endometrial cancer (EC) remains unclear. This study aims to employ bioinformatics methods to identify potential therapeutic targets associated with efferocytosis-related genes in EC. Methods: Transcriptomic and clinical data of EC were obtained from The Cancer Genome Atlas (TCGA) database. Efferocytosis-related genes were curated from published literature. Prognostic genes were identified using random forest and least absolute shrinkage and selection operator (LASSO) regression. A Cox risk score model and nomogram were constructed, followed by random cohort partitioning, internal validation, immune infiltration analysis, and drug sensitivity profiling. Results: A risk score model incorporating oxidized low-density lipoprotein receptor 1 (OLR1), sodium-dependent sulfate (SDS), lysosomal-associated protein transmembrane 5 (LAPTM5), and Src-like adaptor (SLA) effectively stratified patients into high- and low-risk groups. The nomogram, based on risk score, age, and histological grade, accurately predicted the 1-, 3-, and 5-year survival rates of EC patients. Immune infiltration analysis revealed enhanced immune cell activity in the low-risk group. Additionally, 12 drugs sensitive to EC were identified. Conclusions: This study establishes a prognostic model based on efferocytosis-associated genes for EC, providing clinical guidance for the prognosis and treatment of EC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.